A5101877554- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- Eicosanoids and Hypertension Pharmacology
- Pancreatic and Hepatic Oncology Research
- Inflammatory mediators and NSAID effects
- Cancer, Lipids, and Metabolism
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Cancer Mechanisms and Therapy
- Clusterin in disease pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Angiogenesis and VEGF in Cancer
- Liver physiology and pathology
- Protease and Inhibitor Mechanisms
- Ubiquitin and proteasome pathways
- Liver Disease Diagnosis and Treatment
- Cancer Research and Treatments
- Endoplasmic Reticulum Stress and Disease
- Hepatitis B Virus Studies
- Estrogen and related hormone effects
- Xenotransplantation and immune response
- Chemokine receptors and signaling
- Coronary Artery Anomalies
- Histone Deacetylase Inhibitors Research
- RNA Interference and Gene Delivery
Shandong First Medical University
2011-2025
Shandong Provincial Hospital
2022-2025
Shandong Provincial QianFoShan Hospital
2015-2024
Shandong University
2014-2024
Shandong Tumor Hospital
2011-2024
BeiGene (China)
2024
Academy of Medical Sciences
2022
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive human malignancies. The Yes-associated protein-1 (YAP) plays a critical role in cell proliferation, apoptosis and angiogenesis. Verteporfin photosensitizer used photodynamic therapy also small molecular inhibitor Hippo-YAP pathway. However, little known about whether verteporfin could inhibit YAP activity PDAC cells. Our present results showed that suppressed proliferation PANC-1 SW1990 cells by arresting at G1 phase,...
Abstract Notable-HCC (NCT05185531) is a phase 1b trial, aiming to evaluate the safety and preliminary effectiveness of neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT) in early-stage resectable hepatocellular carcinoma (HCC). Twenty patients with HCC BCLC stage 0-A received 3 $$\times $$ <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mo>×</mml:mo> </mml:math> Gy SBRT two cycles tislelizumab, an anti-PD-1 monoclonal antibody before curative resection....
Purpose: Hypoxia-inducible factor-2α (HIF2α) is regarded as a preferential target for individualized hepatocellular carcinoma (HCC) treatment and sorafenib resistance. Our study aimed to identify the regulatory mechanisms of HIF2α activity under hypoxic conditions. We sought determine whether COX-2/PGE2 axis involved in resistance HCC cells.Experimental Design: The cell viability, migration, invasion abilities were measured analyze effects on cells. Both vitro vivo models used driver level...
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in world. Microvascular invasion (MVI) a major risk factor for survival outcomes intrahepatic metastasis after resection patients with HCC. Relevant English literatures retrieved using PubMed on research progress MVI HCC were reviewed. For patients, especially those MVI, it very important to develop comprehensive sequential treatment plan support long-term patients. This manuscript reviewed analyzed factors...
Curcumin, a naturally occurring polyphenolic compound present in turmeric (Curcuma longa), exerts antitumor effects various types of malignancy. However, the precise mechanisms responsible for curcumin on retinoblastoma (RB) cells have not been fully explored. In study, molecular by which its anticancer RB Y79 were investigated. The results showed that reduced cell viability cells. Curcumin induced G1 phase arrest through downregulating expression cyclin D3 and cyclin-dependent kinase...
Aim This study aimed to analyze the effects of perioperative morphine and fentanyl use on delirium, length ICU stay, in-hospital mortality after cardiac surgery. Methods cohort retrieved data 4,596 patients admitted surgery in MIMIC-IV database from 2008 2019. The primary outcome was postoperative delirium. secondary outcomes were mortality. To compare mortality, univariate, two-way stepwise, as well multivariable Logistic regression, linear Cox proportional hazards models respectively used....
To understand the proportion of uHCC (unresectable hepatocellular carcinoma) patients who achieve successful conversion resection in a high-volume setting with state art treatment options.We retrospectively reviewed all HCC hospitalized to our center from June 1st, 2019 2022. Conversion rate, clinicopathological features, response systemic and/or loco-regional therapy and surgical outcomes were analyzed.A total 1,904 identified, 1672 receiving anti-HCC treatment. 328 considered up-front...
Purpose: Systemic therapy has often been used for patients with advanced hepatocellular carcinoma (HCC). However, due to drug resistance, the use of cytotoxic chemotherapy in treatment HCC typically demonstrated low response rates. Secretory clusterin (sCLU) is expressed aggressive late-stage tumors and associated resistance chemotherapy, including that cases. The present research aimed investigate biological role sCLU HCC. Methods: expression normal tissues was examined using...
Abstract Objectives Meloxicam, a selective cyclooxygenase‐2 ( COX ‐2) inhibitor, has been demonstrated to exert anti‐tumour effects against various malignancies. However, up now, mechanisms involved in meloxicam anti‐hepatocellular carcinoma have remained unclear. Materials and methods Cell viability apoptosis were assessed by CCK ‐8 flow cytometry. Endoplasmic reticulum ER ) stress autophagy‐associated molecules analysed western blotting immunofluorescence assay. GRP 78 Atg5 knock‐down si...
Hepatocellular carcinoma (HCC) is regarded as a leading cause of cancer-related deaths, and its progression associated with hypoxia the induction hypoxia-inducible factor (HIF). Meloxicam, selective cyclooxygenase-2 (COX-2) inhibitor, induces cell death in various malignancies. However, underlying mechanism remains to be elucidated HCC, especially under hypoxic conditions. The alteration COX-2 HIF-1 α oncogenicity was evaluated HCC specimens by tissue microarray. Cell viability, angiogenesis...
The P18 peptide is a functional fragment of pigment epithelial-derived factor (PEDF), which an endogenic angiogenesis inhibitor. This study sought to determine the anti-angiogenic bioactivity in hepatocellular carcinoma (HCC) and elucidate underlying mechanism. Xenograft tumour growth assays demonstrated suppressed HCC vivo. Wound healing, Transwell Matrigel-culture indicated that inhibited cell migration tube formation endothelial cells (ECs) vitro. Cell viability apoptosis assessed by...
Recurrence and metastasis are the two leading causes of poor prognosis in patients with hepatocellular carcinoma (HCC). Secreted clusterin (sCLU) is a stress-induced chaperone that overexpressed HCC. However, precise molecular mechanisms sCLU HCC invasion migration largely unknown. In present study, it was indicated downregulation significantly alleviated invasiveness whereas overexpression notably enhanced number invasive cells via mediating expression level MMP-2 E-cadherin Bel-7402...
Hepatocellular carcinoma (HCC) is a prevalent and deadly disease with limited treatment options. Regorafenib, tyrosine kinase inhibitor, has shown promise in HCC but faces limitations as monotherapy. Combining regorafenib PD-1 inhibitor may improve efficacy survival outcomes for patients.This retrospective analysis was conducted to explore its safety, providing reference experience better application of this combination therapy. This single-center study evaluated the safety combining...
Programmed death receptor 1 (PD-1) monoclonal antibody has been approved for the first and second-line treatments of hepatocellular carcinoma (HCC). This study aimed to evaluate efficacy safety tislelizumab + regorafenib as a treatment option advanced HCC.
Secretory clusterin (sCLU) is overexpressed in cancer and associated with resistance to chemotherapy several types of cancer, including hepatocellular carcinoma (HCC). Sorafenib (SOR), a multikinase inhibitor Raf/mitogen‑activated protein kinase kinase/extracellular signal‑regulated (ERK) signaling the receptor tyrosine kinase, recognized as standard therapeutic strategy for patients advanced HCC. However, role sCLU HCC SOR remains be fully elucidated. In present study, was silenced by CLU...
The T7 peptide, an active fragment of full‑length tumstatin [the non‑collagenous 1 domain the type IV collagen α3 chain, (IV) NC1], has exhibited potential antitumor effects in several types cancer cells. However, mechanism underlying its action against human hepatocellular carcinoma (HCC) remains unclear. present study aimed to investigate role autophagy peptide‑induced cytotoxicity HCC cells vitro and vivo. results revealed that peptide significantly reduced cell viability induced cycle...
Liver resection is the mainstay of curative-intent treatment for hepatocellular carcinoma (HCC), but postoperative 5-year recurrence rate reaches 70%, and there are no adjuvant or neoadjuvant therapies recommended by major HCC guidelines that can reduce risk recurrence. In recent decade, significant progress has been achieved in systemic HCC, mainly from immune checkpoint inhibitors (ICIs) targeted therapy. other malignancies, ICIs setting have shown better outcomes than setting. On hand,...
T7 peptide is considered as an antiangiogenic polypeptide. The presents study aimed to further detect the mechanisms of and determine whether combining meloxicam (COX-2/PGE2 specific inhibitor) could offer a better therapy combat hepatocellular carcinoma (HCC). suppressed proliferation, migration, tube formation, promoted apoptosis endothelial cells under both normoxic hypoxic conditions via integrin α3β1 αvβ3 pathways. Cell apoptosis, or formation ability were detected, expression...
To explore the significance of POSSUM scoring system (Physiological and Operative Severity Score for enUmeration Mortality Morbidity) in predicting morbidity mortality elderly Chinese patients undergoing pancreatoduodenectomy (PD).Between January 2001 2011, 396 underwent PD our hospital; P-POSSUM score were retrospectively calculated each patient correlated with observed mortality, respectively.The rates 4.11% 42.8%, respectively. The showed “good fit” prediction (p=0.103), it also but only...
Objective: To investigate the molecular mechanism of nest metastasis in blood vessels encapsulated by tumor clusters (VETC) positive hepatocellular carcinoma (HCC). Methods: A total 72 paraffin embedded HCC tissue samples were collected. Immunohistochemistry staining with CD34 (vascular endothelial cell marker protein) was used to observe morphological manifestations VETC cancer nests primary tumors, bile duct cancerous thrombi and portal vein thrombi, study characteristics hematogenous...
Abstract Background Hepatocellular carcinoma (HCC) is highly invasive, even for early stage HCC, the 1-year post-operative recurrence rates were over a quarter; so far no standard neoadjuvant therapy (NAT) recommended by major guidelines. NAT with immune checkpoint inhibitors (ICIs) has been tried in varying solid tumors including HCC; radiotherapy showed immuno-modulating effect treatment of some malignancies. So we aimed to evaluate safety, tolerability and preliminary effectiveness...